Soutenir la recherche
Je souhaite faire un don
d'un montant de :
The French National Reference Center for Viral Hepatis B, C, and delta
PAWLOTSKY Research Lab - INSERM U955
Department of Virology - Henri Mondor hospital, Public Assistance Paris Hospitals
Viral Hepatitis, Liver Cancer : Everything you need to know !
Publications and Resources
17 December 2018
Conference by Pr CHEVALIEZRead more
6 December 2018
Conference by Pr CHEVALIEZRead more
29 November 2018
Conference by Dr FouratiRead more
On May 1, 1990, I took my internship in Hepatology and Gastroenterology for a semester in the prestigious Department of Hepatology headed by Prof. Daniel Dhumeaux at the Henri Mondor University Hospital in Créteil (University of Paris-Est).This was the beginning of an inspiring translational career, fully dedicated to hepatology and virology.
The adventure started with myself alone, trying to run a home-made PCR for the detection of the RNA of the hepatitis C virus. Hopefully, many collaborators joined the group in the following years. Many of them still belong to it and contribute, at their level, to its production and reputation.
The first step was to put in place an organized, high-quality clinical research setting backed by a modern and innovative molecular virology laboratory. This led to the creation within our laboratory of the French National Reference Center for Viral Hepatitis B, C and D, under the auspices of the French Institute of Health Surveillance. In parallel, the basic research team was created and grew. It was labelled an "INSERM (French National Institute of Health) research team", within the Mondor Institute for Biomedical Research (IMRB, INSERM U955).
Our group provided a major contribution to the evolution of knowledge and to the management of patients with viral hepatitis B and C. This is our common pride. But the world is changing and science is happily bringing solutions to the most complex medical problems. The vast majority of chronic hepatitis C virus infections is now cured, while chronic hepatitis B virus infection is easily controlled by antiviral therapy. It is therefore time for our group to sail to new adventures, taking advantage of the expertise and technological capacity acquired.
We are now moving in 3 complementary directions. The development of novel approaches based on genomics and metagenomics using next-generation sequencing and original bio-analysis software pipelines for the diagnosis of infections. The development of new broad-spectrum antiviral approaches based on the inhibition of cyclophilins and the manipulation of cellular microRNAs, targeted in particular on respiratory viruses, which remain a major challenge for therapeutic developments.The understanding of the role of the hepatic inflammatory microenvironment on the progression of hepatocellular carcinoma and the identification of new therapeutic targets to limit it.
The future belongs to us ...
December 4-5, 2018, Université Paris Est Créteil
9:15-9:30 Welcome, overview of research initiatives/focus at Henri Mondor Jean-Michel Pawlotsky
9:30-10:00 Management of patients with advanced liver disease Isaac Ruiz
10:00-10:30 On our way to HCV elimination: the French model Victor de Lédinghen
11:00-12:00 HCV/HBV case studies presented by the attendees Christophe Hézode and Jean-Michel Pawlotsky
12:00-12:40 The liver in the metabolic syndrome: the cardiologist's viewpoint Geneviève Derumeaux
13:30-13:50 New virological tools to screen, diagnose and monitor HCV Stéphane Chevaliez
13:50-14:10 New virological tools to screen, diagnose and monitor HBV Slim Fourati
14:10-14:30 Non-invasive assessment of liver disease severity (HCV and HBV) Laurent Castéra
14:30-14:50 Next-generation sequencing: principles and applications to viral hepatitis Christophe Rodriguez
15:00-16:00 Site visits
Department of Hepatology Giuliana Amaddeo
Department of Virology Stéphane Chevaliez and Christophe Rodriguez
16:30-16:50 Exploring HCV resistance: the French National Observatory and phenotypic platform Slim Fourati
16:50-17:10 Role of liver immunity in hepatocellular carcinoma occurrence and progression Fouad Lafdil
17:10-17:30 Development of new broad-spectrum host-targeted antiviral approaches Hakim Ahmed-Belkacem
9:30-10:00 Summary of the 2017 EASL Recommendations on HBV treatment Jean-Michel Pawlotsky
10:00-10:30 New HBV therapies in development Jean-Michel Pawlotsky
11:00-12:30 Selected oral presentations from the attendees (6 to 8 presentations)
14:00-14:30 HCC classification Julien Caldéraro
14:30-15:00 HCC imaging Alain Luciani
15:00-15:30 Curative and palliative treatment of HCC Giuliana Amaddeo
15:30-16:00 Future directions in HCC treatment Benoît Rousseau
16:00-16:10 Concluding remarks